Weave Communications, Inc. (WEAV)
NYSEHealth CareSoftware - ApplicationSnapshot 2026-09-04
NYSEHealth CareSoftware - ApplicationSnapshot 2026-09-04
Research Workspace
Put WEAV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve revenue of $275M-$278M for FY26: FY26 revenue guidance $273M-$275M vs target $276.5M.
View ThesisRevenue is growing steadily — about 17% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 59% growth a year, above the roughly 15% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 45% in its worst 12-month stretch.
View RiskWEAV's growth potential hinges on achieving revenue of $275M-$278M for FY26. Recent financial performance shows steady revenue growth, with a 15.5% year-over-year increase in the latest quarter. WEAV trades at 2.3× price-to-sales, compared to a peer median of 1.9×, indicating the market prices in more growth than expected. The primary risk is the guidance cut, with a 22% probability of missing estimates in the next quarter. Peer multiples imply a price about 59% below where it trades (it looks expensive on this basis). Our read is provisional.
Trailing returns as of 2026-09-04. WEAV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering WEAV (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for WEAV in the last 4 months.
Continue this research
Compare WEAV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| WEAV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put WEAV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Stock rating cut may affect investor confidence.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $7.33
The last 12 months of price, then the range of analyst 12-month targets from today’s $7.33.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Buyout deal enhances growth potential and market position.
